-
Zafgen Doubles: What Do The Experts Think?
Thursday, January 21, 2016 - 12:51pm | 388Read More...Recently, analysts from FBR & Co. and RBC Capital Markets gave their take on Zafgen Inc (NASDAQ: ZFGN) after the company's stock price soared on news that their beloranib drug had positive Phase III data. RBC Capital Markets upgraded Zafgen from Sector Perform to Outperform and raised their...
-
Calls Of Note: Shake Shack, Kate Spade And Other Notable Research Notes Worth Following On Tuesday
Tuesday, August 11, 2015 - 10:53am | 1107Read More...The following represents a hand-picked selection of notable research curated by an analyst known in some circles as "The Sith Overlord Of The Street." Longbow: Shake Shack Trends ‘Picking Up,' Maintains At Neutral Alton Stump of Longbow Research maintained a Neutral rating on shares of Shake Shack...
-
UPDATE: Brinson Patrick Initiates Coverage on MannKind
Tuesday, April 8, 2014 - 1:57pm | 154Read More...In a note released Tuesday, Brinson Patrick Initiated coverage on MannKind (NASDAQ: MNKD) at Market Outperform and announced a $12 price target. Brinson Patrick analyst Christopher James emphasized the expected FDA approval of the diabetes drug Afrezza as the main driver for MannKind's Outperform...
